Veracyte, a 2008 start-up company, launched a complex molecular diagnostic test that provides guidance on the potential malignancy of thyroid nodules in record time and with impressive capital efficiency. The company could be a model for the development of high-value diagnostics, especially if it can successfully adopt its approach in a broader market.
